Breast cancer in very young women

European Journal of Surgical Oncology

Volumn 37, Issue 12, 2011, Pages 1030-1037

  Liukkonen, S ^a   Leidenius, M ^a   Saarto, T ^a   Sjostrom Mattson J ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Breast cancer; Locoregional recurrence; Overall survival; Prognosis; Surgery; Young women

Indexed keywords

AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; KI 67 ANTIGEN; METHOTREXATE; NAVELBINE; TAMOXIFEN; TRASTUZUMAB;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARIECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; CHEMORADIOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FINLAND; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY, MODIFIED RADICAL; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; OVARIECTOMY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80955142703     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2011.08.133     Document Type: Article

References (30)

1. www.cancerregistry.fi.
2. C.K. Anders, D.S. Hsu, and G. Broadwater Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression J Clin Oncol 26 20 2008 3324 3330
3. M.C. Hartley, B.P. McKinley, and E.A. Rogers Differential expression of prognostic factors and effect on survival in young (< or = 40) breast cancer patients: a case-control study Am Surg 72 12 2006 1189 1194 discussion 1194-5
4. K. Holli, and J. Isola Effect of age on the survival of breast cancer patients Eur J Cancer 33 3 1997 425 428
5. J.C. Figueiredo, M. Ennis, and J.A. Knight Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study Breast Cancer Res Treat 105 1 2007 69 80
6. J. Seppanen, S. Heinavaara, K. Holli, and T. Hakulinen Comparison of cancer registry and clinical data as predictors for breast cancer survival Cancer Causes Control 19 10 2008 1299 1304
7. J. Lundin, T. Lehtimaki, and M. Lundin Generalisability of survival estimates for patients with breast cancer-a comparison across two population-based series Eur J Cancer 42 18 2006 3228 3235
8. A. Goldhirsch, R.D. Gelber, and G. Yothers Adjuvant therapy for very young women with breast cancer: need for tailored treatments J Natl Cancer Inst Monogr 2001 44 51 (30)
9. N. Bentzon, M. During, B.B. Rasmussen, H. Mouridsen, and N. Kroman Prognostic effect of estrogen receptor status across age in primary breast cancer Int J Cancer 122 5 2008 1089 1094
10. S. Aebi, S. Gelber, and M. Castiglione-Gertsch Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355 9218 2000 1869 1874
11. M. Colleoni, N. Rotmensz, and G. Peruzzotti Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease Ann Oncol 17 10 2006 1497 1503
12. H. Dai, L. van't Veer, and J. Lamb A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients Cancer Res 65 10 2005 4059 4066
13. M. van der Leest, L. Evers, and M.J. van der Sangen The safety of breast-conserving therapy in patients with breast cancer aged < or = 40 years Cancer 109 10 2007 1957 1964
14. M. Clarke, R. Collins, and S. Darby Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Lancet 366 9503 2005 2087 2106
15. M. Kyndi, M. Overgaard, H.M. Nielsen, F.B. Sorensen, H. Knudsen, and J. Overgaard High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c Radiother Oncol 90 1 2009 74 79
16. N. Kroman, H. Holtveg, and J. Wohlfahrt Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma Cancer 100 4 2004 688 693
17. S.J. Anderson, I. Wapnir, and J.J. Dignam Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer J Clin Oncol 27 15 2009 2466 2473
18. P.M. Poortmans, L. Collette, and H. Bartelink The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial Cancer Radiother 12 6-7 2008 565 570
19. H.A. Jones, N. Antonini, and A.A. Hart Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial J Clin Oncol 27 30 2009 4939 4947
20. H. Bartelink, J.C. Horiot, and P. Poortmans Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation N Engl J Med 345 19 2001 1378 1387
21. R. Sharma, I. Bedrosian, and A. Lucci Present-day locoregional control in patients with T1 or T2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy Ann Surg Oncol 2010
22. W.R. Parulekar, A.G. Day, and J.A. Ottaway Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA.5 J Clin Oncol 23 25 2005 6002 6008
23. S. Goel, R. Sharma, A. Hamilton, and J. Beith LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women Cochrane Database Syst Rev 2009 (4):CD004562
24. N. Loman, O. Johannsson, U. Kristoffersson, H. Olsson, and A. Borg Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer J Natl Cancer Inst 93 16 2001 1215 1223
25. S. Samphao, A.J. Wheeler, and E. Rafferty Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging Am J Surg 198 4 2009 538 543
26. K. Syrjakoski, P. Vahteristo, and H. Eerola Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients J Natl Cancer Inst 92 18 2000 1529 1531
27. J.M. Dolle, J.R. Daling, and E. White Risk factors for triple-negative breast cancer in women under the age of 45 years Cancer Epidemiol Biomarkers Prev 18 4 2009 1157 1166
28. M.D. Althuis, D.D. Brogan, and R.J. Coates Breast cancers among very young premenopausal women (United States) Cancer Causes Control 14 2 2003 151 160
29. S.A. Silvera, A.B. Miller, and T.E. Rohan Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study Cancer Causes Control 16 9 2005 1059 1063
30. B. Di Nubila, E. Cassano, and L.A. Urban Radiological features and pathological-biological correlations in 348 women with breast cancer under 35 years old Breast 15 6 2006 744 753